查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1865485

全球自體免疫疾病藥物市場：預測至2032年－按藥物類別、適應症、給藥途徑、通路、最終用戶和地區進行分析

Autoimmune Disease Therapeutics Market Forecasts to 2032 - Global Analysis By Drug Class (Immunosuppressants, Anti-inflammatory Drugs, Corticosteroids and Biosimilars), Indication, Route of Administration, Distribution Channel, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的一項研究，預計到 2025 年，全球自體免疫疾病治療市場價值將達到 71 億美元，到 2032 年將達到 136 億美元，在預測期內的複合年成長率為 9.6%。

自體免疫疾病治療方法旨在治療和緩解免疫系統錯誤攻擊自身健康組織的疾病。這些藥物旨在抑制異常免疫反應、減輕發炎並防止進一步的組織損傷。這些藥物包括皮質類固醇、免疫抑制劑、生技藥品和標靶治療，後者可調節特定的免疫路徑。自體免疫疾病藥物用於治療類風濕性關節炎、全身性紅斑性狼瘡、多發性硬化症和發炎性腸道疾病等疾病。目前的研究和開發重點在於開發更安全、更有效、更個人化的治療方法，以在不損害身體抵抗感染疾病能力的前提下恢復免疫平衡。

疾病盛行率和診斷率不斷上升

由於遺傳易感性、環境誘因和生活方式因素，自體免疫疾病在全球範圍內呈上升趨勢。目前已有成熟的平台可用於輔助免疫調節、症狀管理和疾病進展管理，這些平台採用生物製劑、小分子藥物和標靶治療。與遠端醫療、遠距監測和個人化醫療的整合正在提高治療的可近性和療效。人口老化和高風險族群的增加推動了對擴充性、循證解決方案的需求。這些趨勢正在推動自體免疫疾病醫療保健生態系統中平台應用的普及。

價格壓力和報銷限制

生技藥品和專科藥物需要大量投資，且在管理、監測和支持性護理方面也需要持續投入成本。報銷缺口和分散的支付方政策進一步加劇了藥物可近性和可負擔性的難題。企業在定價模式與臨床療效和病人參與之間尋求平衡方面面臨挑戰。供應商必須提供基於價值的合約、生物相似藥選擇以及成本透明的平台，以提高藥物的普及率。這些限制因素持續阻礙低收入和無保險族群中此類平台的成熟。

標靶生技藥品和小分子藥物的進展

為了避免等待時間並提高便利性，患者越來越傾向於選擇遠距醫療和居家監測。相關平台可連接行動應用、雲端基礎分析和穿戴式感測器，提供即時洞察和個人化護理。基層醫療、雇主主導的健康計劃和保險援助計劃對擴充性且符合隱私保護要求的解決方案的需求日益成長。供應商正在提供模組化套件、人工智慧驅動的分流系統和結果儀表板，以支援混合護理模式。

競爭與生物相似藥的進入

許多地區缺乏訓練有素的專業人員、診斷檢查室和報銷機制，難以支持廣泛的篩檢和治療。文化偏見、健康素養低以及數位接取受限進一步降低了需求和參與。企業在向農村和城鄉結合部人口部署可擴展、擴充性的解決方案方面面臨挑戰。供應商必須透過教育宣傳活動、行動優先平台以及對公私合營的投資來擴大其覆蓋範圍。

新冠疫情的影響：

疫情擾亂了全球免疫診所、診斷流程和治療順從性。封鎖措施導致面對面就診延遲，並減少了患者接觸專家和輸液中心的機會。疫情後的恢復期，自體免疫疾病的治療重點轉向遠距遠端醫療、數位化診斷和病患自我管理。醫療系統和消費者管道對遠端監測、人工智慧篩檢和家庭治療的投資激增。政策制定者和臨床醫生越來越意識到免疫健康與感染風險以及慢性病管理之間的關聯。

預計在預測期內，生技藥品領域將佔據最大的市場佔有率。

由於生物製劑在治療上具有重要意義，且擁有創新開發平臺，並在自體免疫疾病領域展現出臨床療效，預計在預測期內，生技藥品領域將佔據最大的市場佔有率。生物製劑平台可支持抗發炎、免疫抑制和標靶干預，可作為傳統治療方法的補充。與個人化醫療、生物標記追蹤和聯合通訊協定的整合，能夠改善治療效果並最佳化患者分層。對於慢性或難治性病例，非類固醇類藥物和基於精準醫療的治療方法需求日益成長。供應商提供單株抗體、融合蛋白和細胞激素調節劑，旨在滿足自體免疫疾病的特徵。

預計在預測期內，發炎性腸道疾病細分市場將呈現最高的複合年成長率。

隨著自體免疫平台拓展至消化器官系統和全身發炎管理領域，預計發炎性腸道疾病領域將在預測期內達到最高成長率。克隆氏症和潰瘍性大腸炎等疾病的發生率因飲食習慣改變、腸道菌叢失調和遺傳易感性而不斷上升。該平台有助於追蹤症狀、預測病情復發，並將胃腸道和免疫學工作流程中的護理整合起來。與遠端醫療、穿戴式感測器和患者報告結果的整合，能夠改善個人化治療並提高患者依從性。專科診所、支付方網路和人群健康計劃對擴充性的多學科解決方案的需求日益成長。

佔比最大的地區：

由於人口密度高、疾病負擔加重以及自體免疫治療領域的醫療現代化，預計亞太地區將在預測期內佔據最大的市場佔有率。中國、印度、日本和韓國等國家正在都市區醫院、企業健康計畫和公共衛生計畫中拓展平台應用。政府主導的措施正在支持慢性病管理的基礎設施建設、數位醫療應用和宣傳宣傳活動。本地醫療服務提供者正在提供經濟高效、符合當地文化且以行動端為先的解決方案，以滿足當地需求。都市區和近郊市場對擴充性且整體性的自體免疫疾病基礎設施的需求日益成長。

預計年複合成長率最高的地區：

在預測期內，隨著自體免疫疾病技術的創新、報銷和臨床應用不斷融合，北美預計將成為複合年成長率最高的地區。各公司正在居家醫療、遠端醫療和綜合護理網路中部署平台，以改善醫療服務的可近性和治療效果。對人工智慧診斷、生技藥品和數位療法的投資支持了擴充性和個人化治療。主要供應商、學術機構和支付方框架的存在正在推動生態系統的成熟和創新。各公司正在將自體免疫疾病策略與基於價值的醫療、慢性病管理和雇主健康目標相協調。這些趨勢正在推動北美自體免疫疾病基礎設施和治療平台的區域成長。

免費客製化服務

訂閱本報告的用戶可從以下免費自訂選項中選擇一項：

  • 公司簡介
    • 對最多三家其他公司進行全面分析
    • 對主要企業進行SWOT分析（最多3家公司）
  • 區域分類
    • 根據客戶興趣對主要國家進行市場估算、預測和複合年成長率分析（註：基於可行性檢查）
  • 競爭基準化分析
    • 基於產品系列、地域覆蓋和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 引言

  • 概述
  • 相關利益者
  • 分析範圍
  • 分析方法
    • 資料探勘
    • 數據分析
    • 數據檢驗
    • 分析方法
  • 分析材料
    • 原始研究資料
    • 二手研究資訊來源
    • 先決條件

第3章 市場趨勢分析

  • 介紹
  • 促進要素
  • 抑制因素
  • 市場機遇
  • 威脅
  • 終端用戶分析
  • 新興市場
  • 新冠疫情的感染疾病

第4章 波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代產品的威脅
  • 新參與企業的威脅
  • 公司間的競爭

5. 全球自體免疫疾病藥物市場（依藥物類別分類）

  • 介紹
  • 免疫抑制劑
  • 抗發炎藥
  • 皮質類固醇
  • 非類固醇消炎劑（NSAIDs）
  • 生技藥品
    • TNF抑制劑
    • 白細胞介素抑制劑
    • B細胞和T細胞調變器
  • 生物相似藥

6. 全球自體免疫疾病藥物市場（依適應症分類）

  • 介紹
  • 類風濕性關節炎
  • 銀屑病、乾癬性關節炎
  • 發炎性腸道疾病（克隆氏症、潰瘍性大腸炎）
  • 全身性紅斑性狼瘡
  • 多發性硬化症
  • 1型糖尿病
  • 僵直性脊椎炎
  • 其他跡象

7. 全球自體免疫疾病藥物市場（依給藥途徑分類）

  • 介紹
  • 口服
  • 注射
  • 靜脈

8. 全球自體免疫疾病治療市場（依通路分類）

  • 介紹
  • 醫院藥房
  • 零售藥房
  • 網路藥房
  • 專科診所

9. 全球自體免疫疾病治療市場（依最終用戶分類）

  • 介紹
  • 醫院
  • 診所
  • 居家醫療
  • 研究和學術機構
  • 其他最終用戶

第10章 全球自體免疫疾病治療市場（按地區分類）

  • 介紹
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 亞太其他地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美洲
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第11章：主要趨勢

  • 合約、商業夥伴關係和合資企業
  • 企業合併（M&A）
  • 新產品發布
  • 業務拓展
  • 其他關鍵策略

第11章：公司簡介

  • AbbVie Inc.
  • Johnson & Johnson Services Inc.
  • Pfizer Inc.
  • Amgen Inc.
  • Novartis AG
  • F. Hoffmann-La Roche Ltd.
  • Bristol-Myers Squibb Company
  • Sanofi SA
  • Eli Lilly and Company
  • Takeda Pharmaceutical Company Limited
  • UCB SA
  • Biogen Inc.
  • Gilead Sciences Inc.
  • AstraZeneca PLC
  • Merck & Co., Inc.
Product Code: SMRC32187

According to Stratistics MRC, the Global Autoimmune Disease Therapeutics Market is accounted for $7.1 billion in 2025 and is expected to reach $13.6 billion by 2032 growing at a CAGR of 9.6% during the forecast period. Autoimmune Disease Therapeutics refers to treatments designed to manage and alleviate conditions in which the immune system mistakenly attacks the body's own healthy tissues. These therapeutics aim to suppress abnormal immune responses, reduce inflammation, and prevent further tissue damage. They include drugs such as corticosteroids, immunosuppressants, biologics, and targeted therapies that modulate specific immune pathways. Autoimmune disease therapeutics are used to treat disorders like rheumatoid arthritis, lupus, multiple sclerosis, and inflammatory bowel disease. Ongoing research focuses on developing safer, more effective, and personalized treatments that restore immune balance without compromising the body's defense against infections.

Market Dynamics:

Driver:

Rising disease prevalence & diagnosis rates

Autoimmune conditions are increasing globally due to genetic predisposition environmental triggers and lifestyle factors. Platforms support immunomodulation symptom control and disease progression management using biologics small molecules and targeted therapies. Integration with telehealth remote monitoring and personalized medicine enhances accessibility and treatment outcomes. Demand for scalable and evidence-based solutions is rising across aging populations and high-risk cohorts. These dynamics are propelling platform deployment across autoimmune-focused care ecosystems.

Restraint:

Pricing pressure & reimbursement limits

Biologics and specialty drugs require significant investment and recurring expenses for administration monitoring and supportive care. Reimbursement gaps and fragmented payer policies further complicate access and affordability. Enterprises face challenges in aligning pricing models with clinical outcomes and patient engagement. Vendors must offer value-based contracts biosimilar options and cost-transparent platforms to improve uptake. These constraints continue to hinder platform maturity across low-income and underinsured populations.

Opportunity:

Advances in targeted biologics & small molecules

Patients increasingly prefer virtual consultations and home-based monitoring to avoid clinical wait times and improve convenience. Platforms integrate with mobile apps cloud-based analytics and wearable sensors to deliver real-time insights and personalized therapy. Demand for scalable and privacy-compliant solutions is rising across primary care employer wellness and insurance-backed programs. Vendors offer modular kits AI-driven triage and outcome dashboards to support hybrid care models.

Threat:

Competition and biosimilar entry

Many regions lack trained specialists diagnostic labs and reimbursement frameworks to support widespread screening and treatment. Cultural stigma low health literacy and limited digital access further degrade demand and engagement. Enterprises face challenges in deploying scalable and regionally adapted solutions across rural and peri-urban populations. Vendors must invest in education campaigns mobile-first platforms and public-private partnerships to expand reach.

Covid-19 Impact:

The pandemic disrupted immunology clinics diagnostic workflows and therapy adherence across global markets. Lockdowns delayed in-person visits and reduced access to specialists and infusion centers. Post-pandemic recovery emphasized remote care digital diagnostics and patient self-management across autoimmune medicine. Investment in telemonitoring AI screening and home-based therapy surged across healthcare systems and consumer channels. Public awareness of immune health and its link to infection risk and chronic disease management increased across policy and clinical circles.

The biologics segment is expected to be the largest during the forecast period

The biologics segment is expected to account for the largest market share during the forecast period due to its therapeutic relevance, innovation pipeline, and clinical efficacy across autoimmune conditions. Platforms support anti-inflammatory, immunosuppressive, and targeted interventions that complement conventional therapies. Integration with personalized medicine, biomarker tracking, and combination protocols enhances treatment outcomes and patient stratification. Demand for non-steroidal and precision-driven options is rising across chronic and refractory cases. Vendors offer monoclonal antibodies, fusion proteins, and cytokine modulators tailored to autoimmune disease profiles.

The inflammatory bowel disease segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the inflammatory bowel disease segment is predicted to witness the highest growth rate as autoimmune platforms expand across gastrointestinal and systemic inflammation management. Conditions such as Crohn's disease and ulcerative colitis are increasing due to dietary shifts, microbiome disruption, and genetic susceptibility. Platforms support symptom tracking, flare prediction, and integrated care across gastroenterology and immunology workflows. Integration with telehealth, wearable sensors, and patient-reported outcomes enhances personalization and adherence. Demand for scalable and cross-specialty solutions is rising across specialty clinics, payer networks, and public health programs.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share due to its population density, rising disease burden, and healthcare modernization across autoimmune medicine. Countries like China, India, Japan, and South Korea scale platforms across urban hospitals, employer wellness, and public health programs. Government-backed initiatives support infrastructure development, digital health adoption, and awareness campaigns across chronic disease management. Local providers offer cost-effective, culturally adapted, and mobile-first solutions tailored to regional needs. Demand for scalable and inclusive autoimmune infrastructure is rising across urban and peri-urban markets.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR as innovation, reimbursement, and clinical adoption converge across autoimmune disease technologies. Enterprises deploy platforms across homecare, telehealth, and integrated care networks to improve access and outcomes. Investment in AI diagnostics, biologics, and digital therapeutics supports scalability and personalization. Presence of leading vendors, academic institutions, and payer frameworks drives ecosystem maturity and innovation. Firms align autoimmune strategies with value-based care, chronic disease management, and employer wellness goals. These trends are accelerating regional growth across North America's autoimmune disease infrastructure and therapeutic platforms.

Key players in the market

Some of the key players in Autoimmune Disease Therapeutics Market include AbbVie Inc., Johnson & Johnson Services Inc., Pfizer Inc., Amgen Inc., Novartis AG, F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, Sanofi S.A., Eli Lilly and Company, Takeda Pharmaceutical Company Limited, UCB S.A., Biogen Inc., Gilead Sciences Inc., AstraZeneca PLC and Merck & Co., Inc.

Key Developments:

In June 2025, AbbVie announced a definitive agreement to acquire Capstan Therapeutics for up to $2.1 billion, and completed the transaction. Capstan's lead asset, CPTX2309, is a targeted lipid nanoparticle (tLNP) delivering mRNA encoding anti-CD19 CAR to CD8+ T cells. The acquisition added a potential first-in-class therapy for B cell-mediated autoimmune diseases, aiming for durable, drug-free remission.

In October 2023, Amgen completed the $27.8 billion acquisition of Horizon Therapeutics plc, gaining access to first-in-class therapies for rare autoimmune diseases. The deal added Tepezza (thyroid eye disease) and Krystexxa (chronic gout) to Amgen's portfolio, significantly expanding its reach in immunology and inflammation markets.

Drug Classes Covered:

  • Immunosuppressants
  • Anti-inflammatory Drugs
  • Corticosteroids
  • Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
  • Biologics
  • Biosimilars

Indications Covered:

  • Rheumatoid Arthritis
  • Psoriasis & Psoriatic Arthritis
  • Inflammatory Bowel Disease (Crohn's Disease, Ulcerative Colitis)
  • Systemic Lupus Erythematosus
  • Multiple Sclerosis
  • Type 1 Diabetes
  • Ankylosing Spondylitis
  • Other Indications

Route of Administrations Covered:

  • Oral
  • Injectable
  • Intravenous

Distribution Channels Covered:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Specialty Clinics

End Users Covered:

  • Hospitals
  • Clinics
  • Homecare Settings
  • Research & Academic Institutes
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Autoimmune Disease Therapeutics Market, By Drug Class

  • 5.1 Introduction
  • 5.2 Immunosuppressants
  • 5.3 Anti-inflammatory Drugs
  • 5.4 Corticosteroids
  • 5.5 Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
  • 5.6 Biologics
    • 5.6.1 TNF Inhibitors
    • 5.6.2 Interleukin Inhibitors
    • 5.6.3 B-cell and T-cell Modulators
  • 5.7 Biosimilars

6 Global Autoimmune Disease Therapeutics Market, By Indication

  • 6.1 Introduction
  • 6.2 Rheumatoid Arthritis
  • 6.3 Psoriasis & Psoriatic Arthritis
  • 6.4 Inflammatory Bowel Disease (Crohn's Disease, Ulcerative Colitis)
  • 6.5 Systemic Lupus Erythematosus
  • 6.6 Multiple Sclerosis
  • 6.7 Type 1 Diabetes
  • 6.8 Ankylosing Spondylitis
  • 6.9 Other Indications

7 Global Autoimmune Disease Therapeutics Market, By Route of Administration

  • 7.1 Introduction
  • 7.2 Oral
  • 7.3 Injectable
  • 7.4 Intravenous

8 Global Autoimmune Disease Therapeutics Market, By Distribution Channel

  • 8.1 Introduction
  • 8.2 Hospital Pharmacies
  • 8.3 Retail Pharmacies
  • 8.4 Online Pharmacies
  • 8.5 Specialty Clinics

9 Global Autoimmune Disease Therapeutics Market, By End User

  • 9.1 Introduction
  • 9.2 Hospitals
  • 9.3 Clinics
  • 9.4 Homecare Settings
  • 9.5 Research & Academic Institutes
  • 9.6 Other End Users

10 Global Autoimmune Disease Therapeutics Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 AbbVie Inc.
  • 12.2 Johnson & Johnson Services Inc.
  • 12.3 Pfizer Inc.
  • 12.4 Amgen Inc.
  • 12.5 Novartis AG
  • 12.6 F. Hoffmann-La Roche Ltd.
  • 12.7 Bristol-Myers Squibb Company
  • 12.8 Sanofi S.A.
  • 12.9 Eli Lilly and Company
  • 12.10 Takeda Pharmaceutical Company Limited
  • 12.11 UCB S.A.
  • 12.12 Biogen Inc.
  • 12.13 Gilead Sciences Inc.
  • 12.14 AstraZeneca PLC
  • 12.15 Merck & Co., Inc.

List of Tables

  • Table 1 Global Autoimmune Disease Therapeutics Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Autoimmune Disease Therapeutics Market Outlook, By Drug Class (2024-2032) ($MN)
  • Table 3 Global Autoimmune Disease Therapeutics Market Outlook, By Immunosuppressants (2024-2032) ($MN)
  • Table 4 Global Autoimmune Disease Therapeutics Market Outlook, By Anti-inflammatory Drugs (2024-2032) ($MN)
  • Table 5 Global Autoimmune Disease Therapeutics Market Outlook, By Corticosteroids (2024-2032) ($MN)
  • Table 6 Global Autoimmune Disease Therapeutics Market Outlook, By Nonsteroidal Anti-inflammatory Drugs (NSAIDs) (2024-2032) ($MN)
  • Table 7 Global Autoimmune Disease Therapeutics Market Outlook, By Biologics (2024-2032) ($MN)
  • Table 8 Global Autoimmune Disease Therapeutics Market Outlook, By TNF Inhibitors (2024-2032) ($MN)
  • Table 9 Global Autoimmune Disease Therapeutics Market Outlook, By Interleukin Inhibitors (2024-2032) ($MN)
  • Table 10 Global Autoimmune Disease Therapeutics Market Outlook, By B-cell and T-cell Modulators (2024-2032) ($MN)
  • Table 11 Global Autoimmune Disease Therapeutics Market Outlook, By Biosimilars (2024-2032) ($MN)
  • Table 12 Global Autoimmune Disease Therapeutics Market Outlook, By Indication (2024-2032) ($MN)
  • Table 13 Global Autoimmune Disease Therapeutics Market Outlook, By Rheumatoid Arthritis (2024-2032) ($MN)
  • Table 14 Global Autoimmune Disease Therapeutics Market Outlook, By Psoriasis & Psoriatic Arthritis (2024-2032) ($MN)
  • Table 15 Global Autoimmune Disease Therapeutics Market Outlook, By Inflammatory Bowel Disease (Crohn's Disease, Ulcerative Colitis) (2024-2032) ($MN)
  • Table 16 Global Autoimmune Disease Therapeutics Market Outlook, By Systemic Lupus Erythematosus (2024-2032) ($MN)
  • Table 17 Global Autoimmune Disease Therapeutics Market Outlook, By Multiple Sclerosis (2024-2032) ($MN)
  • Table 18 Global Autoimmune Disease Therapeutics Market Outlook, By Type 1 Diabetes (2024-2032) ($MN)
  • Table 19 Global Autoimmune Disease Therapeutics Market Outlook, By Ankylosing Spondylitis (2024-2032) ($MN)
  • Table 20 Global Autoimmune Disease Therapeutics Market Outlook, By Other Indications (2024-2032) ($MN)
  • Table 21 Global Autoimmune Disease Therapeutics Market Outlook, By Route of Administration (2024-2032) ($MN)
  • Table 22 Global Autoimmune Disease Therapeutics Market Outlook, By Oral (2024-2032) ($MN)
  • Table 23 Global Autoimmune Disease Therapeutics Market Outlook, By Injectable (2024-2032) ($MN)
  • Table 24 Global Autoimmune Disease Therapeutics Market Outlook, By Intravenous (2024-2032) ($MN)
  • Table 25 Global Autoimmune Disease Therapeutics Market Outlook, By Distribution Channel (2024-2032) ($MN)
  • Table 26 Global Autoimmune Disease Therapeutics Market Outlook, By Hospital Pharmacies (2024-2032) ($MN)
  • Table 27 Global Autoimmune Disease Therapeutics Market Outlook, By Retail Pharmacies (2024-2032) ($MN)
  • Table 28 Global Autoimmune Disease Therapeutics Market Outlook, By Online Pharmacies (2024-2032) ($MN)
  • Table 29 Global Autoimmune Disease Therapeutics Market Outlook, By Specialty Clinics (2024-2032) ($MN)
  • Table 30 Global Autoimmune Disease Therapeutics Market Outlook, By End User (2024-2032) ($MN)
  • Table 31 Global Autoimmune Disease Therapeutics Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 32 Global Autoimmune Disease Therapeutics Market Outlook, By Clinics (2024-2032) ($MN)
  • Table 33 Global Autoimmune Disease Therapeutics Market Outlook, By Homecare Settings (2024-2032) ($MN)
  • Table 34 Global Autoimmune Disease Therapeutics Market Outlook, By Research & Academic Institutes (2024-2032) ($MN)
  • Table 35 Global Autoimmune Disease Therapeutics Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.